Interaction of chloramphenicol with phenytoin and phenobarbital. Case report. 1978

J R Koup, and M Gibaldi, and P McNamara, and D M Hilligoss, and W A Colburn, and E Bruck

The effect of chloramphenicol therapy (48 mg/kg/day) on the serum concentrations of phenytoin and phenobarbital was studied in a patient previously stabilized on anticonvulsant medications. Phenytoin, 12 mg/kg/day, and phenobarbital, 5 mg/kg/day resulted in serum concentrations averaging 10.8 microgram/ml before and 30.5 microgram/ml, after chloramphenicol therapy. A reduction in dose of both phenytoin and phenobarbital was required to minimize adverse effects during the course of chloramphenicol therapy. An average daily dose of phenytoin of 9.1 mg/kg resulted in an average serum concentration of 17.8 microgram/ml. A daily dose of phenobarbital of 4.0 mg/kg resulted in an average serum concentration of 37.1 microgram/ml. These changes indicate 50.5% and 40.4% decreases in clearance of phenytoin and phenobarbital. Multiple-dose nonlinear regression analysis of phenytoin and phenobarbital serum concentration data obtained during chloramphenicol therapy indicated a 62.5% and a 29.5% decrease in clearance. Subsequent serum concentration monitoring demonstrated a similar reduction in phenobarbital clearance when chloramphenicol was added to phenobarbital alone.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D010634 Phenobarbital A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. Phenemal,Phenobarbitone,Phenylbarbital,Gardenal,Hysteps,Luminal,Phenobarbital Sodium,Phenobarbital, Monosodium Salt,Phenylethylbarbituric Acid,Acid, Phenylethylbarbituric,Monosodium Salt Phenobarbital,Sodium, Phenobarbital
D010672 Phenytoin An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs. Diphenylhydantoin,Fenitoin,Phenhydan,5,5-Diphenylhydantoin,5,5-diphenylimidazolidine-2,4-dione,Antisacer,Difenin,Dihydan,Dilantin,Epamin,Epanutin,Hydantol,Phenytoin Sodium,Sodium Diphenylhydantoinate,Diphenylhydantoinate, Sodium
D002701 Chloramphenicol An antibiotic first isolated from cultures of Streptomyces venequelae in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106) Cloranfenicol,Kloramfenikol,Levomycetin,Amphenicol,Amphenicols,Chlornitromycin,Chlorocid,Chloromycetin,Detreomycin,Ophthochlor,Syntomycin
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

J R Koup, and M Gibaldi, and P McNamara, and D M Hilligoss, and W A Colburn, and E Bruck
January 1982, Pediatric infectious disease,
J R Koup, and M Gibaldi, and P McNamara, and D M Hilligoss, and W A Colburn, and E Bruck
January 2015, The Central African journal of medicine,
J R Koup, and M Gibaldi, and P McNamara, and D M Hilligoss, and W A Colburn, and E Bruck
December 2012, International journal of clinical pharmacology and therapeutics,
J R Koup, and M Gibaldi, and P McNamara, and D M Hilligoss, and W A Colburn, and E Bruck
July 1988, Pharmacological research communications,
J R Koup, and M Gibaldi, and P McNamara, and D M Hilligoss, and W A Colburn, and E Bruck
June 1981, The Journal of pediatrics,
J R Koup, and M Gibaldi, and P McNamara, and D M Hilligoss, and W A Colburn, and E Bruck
June 1977, JAMA,
J R Koup, and M Gibaldi, and P McNamara, and D M Hilligoss, and W A Colburn, and E Bruck
July 1979, Journal of the American Veterinary Medical Association,
J R Koup, and M Gibaldi, and P McNamara, and D M Hilligoss, and W A Colburn, and E Bruck
November 2011, Indian journal of pharmacology,
J R Koup, and M Gibaldi, and P McNamara, and D M Hilligoss, and W A Colburn, and E Bruck
January 1979, Folia psychiatrica et neurologica japonica,
J R Koup, and M Gibaldi, and P McNamara, and D M Hilligoss, and W A Colburn, and E Bruck
March 2021, Clinical case reports,
Copied contents to your clipboard!